BIAF · bioAffinity Technologies, Inc. · Analyst Estimates
$1.76
-0.09 (-4.86%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at September 30, 2026, of $2.6 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Nov 6, 2026
Market Cap
$3.37M
Shares
1.82M
Volume · Nov 20
16.51K
Avg daily vol (63 sessions)
3.6M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for bioAffinity Technologies, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-15 10:46 UTC · Publication dates shown per estimate · 2 metric / period groups
FY ending 2025-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Q ending 2026-03-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Key facts
CIK
1712762
CUSIP
09076W406
13F (30d)
21 filings
14 filers
Visit website
Investor relations